The Nanobiotix SA – ADR (NASDAQ: NBTX) stock price soared 107.9% after revealing that it is entering final contract negotiations with a major global pharmaceutical company to commercialise its lead nanotherapeutic candidate NBTXR3.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
The two companies had already signed a non-binding term sheet for developing and commercialising NBTXR3. The drug candidate is a novel, potentially first-in-class oncology product of functionalized hafnium oxide nanoparticles. NBTX3 is delivered via one-time intratumoral injection and activated by radiotherapy.
WELCOME BONUS - Free Share Bundle When You Invest £50!
Get up to £500 cashback for investing with IG.
Top Broker Recommendation
- IG Top-tier regulation – Read our Review
- eToro Wide range of instruments available to trade – Read our Review
YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY
NBTX3’s physical mechanism of action (MoA) can trigger significant tumor cell death in the injected tumor once it is activated via radiotherapy. Subsequently, the drug will trigger an adaptive immune response and a long-term anti-cancer memory.
Given NBTX3’s physical MoA, Nanobiotix is convinced that the drug could be scaled across any solid tumor that can be treated using radiotherapy. The drug can also be combined with other therapies, especially immune checkpoint inhibitors.
NBTX3 is being evaluated as s treatment for locally advanced head and neck squamous cell carcinoma (HNSCC) and is positioned as the primary development pathway. Nanobiotix noted that its Phase 1 dose escalation and expansion study had generated positive safety data, showing early efficacy signs.
NAnobioticx launched a phase 3 registrational study in 2021. In February 2020, the US Food and Drug Administration (FDA) granted regulatory fast-track designation for the investigation of NBTX3 when activated by radiation therapy.
The drug was tested with or without cetuximab as a treatment for patients suffering from locally advanced HNSCC that were not eligible for platinum-based chemotherapy. This was the same population being studied in the Phase 3 study.
Nanobiotix has also prioritized an Immuno-Oncology development program that started with a company-sponsored Phase 1 clinical trial evaluating NBTX3 when activated by radiotherapy combined with anti-PD-1 checkpoint inhibitors for patients with locoregional recurrent or metastatic HNSCC.
The drug was also tested against lung or liver metastases from any primary cancer eligible for anti-PD-1 therapy. Nanobiotix has engaged in a strategic collaboration system with world-class partners to expand the development of NBTX3 in parallel with its priority development channels.
*This is not investment advice.
Nanobiotix (NBTX) stock price.
The Nanobiotix (NBTX) stock price soared 107.88% to trade at $4.22, from Thursday’s closing price of $2.03.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.